ALS Ride for Life is launching its 20th annual ride and celebrating the anniversary with another event to raise awareness and funds to accelerate the discovery of a cure for amyotrophic lateral sclerosis (ALS). Chris Pendergast founded Ride for Life in 1997 after being diagnosed with ALS in…
Defects in RNA processing and transport, as well as protein folding, may contribute to amyotrophic lateral sclerosis (ALS) pathology, according to the results of recent research. The study, “Altered nucleocytoplasmic proteome and transcriptome distributions in an in vitro model of amyotrophic lateral sclerosis,” was published in the journal PLOS…
Pfizer and AbbVie are pumping $10 million into Aquinnah Pharmaceuticals‘ effort to develop a revolutionary approach to treating neurodegenerative diseases — one that could arrest, or even reverse, the progression of Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s and other conditions. Takeda Pharmaceuticals invested $5 million in Aquinnah’s program in December 2015.
May is ALS Awareness Month and the ALS community is seeking the help of individuals willing to participate, advocate and donate to advance the fight toward a world free of amyotrophic lateral sclerosis, commonly known as “Lou Gehrig’s Disease.” The ALS Association is a national non-profit organization dedicated to building…
Biohaven Pharmaceuticals is pushing hard for regulatory approval and development of its two investigational drugs for amyotrophic lateral sclerosis (ALS): BHV-0223, a sublingual form of Rilutek (riluzole), and BHV-4157, a compound that modulates the neurotransmitter glutamate. After more than 20 years, Rilutek remains the only approved treatment for people with…
More amyotrophic lateral sclerosis (ALS) patients survived among those who completed a Phase 2 trial of MediciNova’s Ibudilast (MN-166), compared to those who dropped out of the study, according to an exploratory interim analysis. But the data, presented at the American Academy of Neurology (AAN) 2017 Annual Meeting…
The amyotrophic lateral sclerosis (ALS) investigational drug edaravone will be the focus of four presentations by MT Pharma America in Boston. The presentations, which include data on edaravone and an analysis evaluating clinically relevant symptoms of ALS, are taking place at the 69th Annual Meeting of the American…
Amyotrophic lateral sclerosis (ALS) and schizophrenia may be caused by similar gene mutations that affect the way neurons work, according to new research. Researchers found that 14.3 percent of the genetic variations linked to ALS were also present in people with schizophrenia, suggesting the diseases may be related. The study,…
A compound that stabilizes a protein crucial for the survival of motor neurons helped cells of amyotrophic lateral sclerosis (ALS) patients survive longer in experiments performed in lab dishes. The discovery builds on research about a childhood neuromuscular disease — spinal muscular atrophy (SMA) — and may lead to new treatments…
Insights into the behavior of TDP-43 — a key protein in amyotrophic lateral sclerosis (ALS) development — may offer clues in preventing protein aggregation, potentially leading to new treatments for the disease. And the new level of understanding of how the protein is controlled and what it does in the cell…
